Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by canadafanon Nov 06, 2024 7:44pm

129 Views

Post# 36300000

most recent target from nasdaq

Hello Bucky, agaiin I feel for your complete lack of reading abilities.
Sad actuzlly.
anyhwo to make life easy for you a screen shot from Nasdaq
listed under ONCY ( that being USA dollars)
I uunderstand about $1.29. Would equate to $6.95 CDN.
Im sure you & your bashing crew are well awre of the Nasdaq
going back a few years the consensus was above $8PS. They have come down relating to the alternative market for the MBc applications.
None of the anlaysts are couting in the Pancreatic cancer.

Exchange

NASDAQ-CM

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

1 Year Target

$5.00

Today's High/Low

$1.18/$1.105

Share Volume

390,870